GET DAILY SIGNALSAC Immune (ACIU) Q3 2026 Earnings Preview: What Investors Need to Know
Key Takeaways
- AC Immune is expected to report third-quarter 2026 results before the market opens in early November, followed by a conference call.
- Wall Street consensus projects a net loss of about $0.22 per share, compared with a loss of $0.20 in the same quarter a year ago.
- Analysts model roughly $0.33 million in revenue, a sharp decline from $1.18 million a year earlier, reflecting milestone-driven lumpiness.
- In its prior quarter, the company swung to earnings per share (EPS) of $0.03 on $18.67 million in revenue, boosted by a milestone payment.
- Cash runway and research and development (R&D) spending remain central as the company advances its Alzheimer's and Parkinson's programs.
- The stock has lagged over the past year, sharpening investor focus on guidance and pipeline catalysts.
Understanding the Earnings Context
AC Immune is a Swiss clinical-stage biopharmaceutical company developing precision medicines for neurodegenerative diseases such as Alzheimer's and Parkinson's. Because it generates limited product revenue, its quarterly results hinge on collaboration income and milestone payments, which can swing dramatically from one period to the next. For investors, the report is less about headline profitability and more about three signals: how efficiently the company is spending its cash, whether key clinical programs are progressing on schedule, and whether the balance sheet provides enough runway to reach the next data readouts. Given the stock's elevated short interest and a 52-week decline, this update carries added weight for sentiment.
Earnings Expectations
Consensus estimates call for AC Immune to post a loss of approximately $0.22 per share on revenue of about $0.33 million for the third quarter of 2026. That compares with a loss of $0.20 per share and revenue of $1.18 million in the prior-year period, implying a revenue decline of roughly 72%. The expected drop largely reflects the timing of collaboration and milestone revenue rather than underlying weakness. Notably, the company beat EPS estimates in five of its last eight quarters, and its most recent report, for Q2 2026, swung to a profit of $0.03 per share on $18.67 million in revenue after a milestone payment. Beyond the headline figures, investors will watch R&D expenses, net cash, and any updates on clinical enrollment and partnership milestones. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Investor Sentiment
Sentiment heading into the print is cautious. AC Immune shares have declined over the past 52 weeks, and the stock carries a beta of about 1.55, meaning it tends to be more volatile than the broader market. Short interest stands near 7.6% of shares outstanding, a level that can amplify both upside and downside moves around a catalyst. Still, analyst sentiment remains constructive, with a consensus rating generally characterized as a "Buy" and a mean price target well above the current price. The key risk is that, without a fresh milestone or positive clinical update, a routine quarterly loss may do little to shift the narrative, leaving the stock exposed to profit-taking or continued drift.
Forward Outlook and Key Factors to Monitor
Looking ahead, the most important factor is the company's cash position and how far it extends the operating runway. AC Immune ended recent periods with a net cash position well above its market value on a per-share basis, but ongoing R&D spending means that runway depends on disciplined cost control and the arrival of future milestone payments.
Investors should also watch for progress across the Alzheimer's and Parkinson's portfolio. Enrollment updates, regulatory feedback, and any new or expanded partnerships are likely to matter more to the stock than a single quarter's revenue figure. Because collaboration income is lumpy, quarter-to-quarter comparisons can be misleading; the longer-term trajectory of partnered programs is the better signal.
Finally, pay attention to guidance and management commentary on the earnings call. Any adjustment to spending plans, updated timelines for data readouts, or changes to the pipeline's prioritization could shape expectations for 2027, when consensus currently models a return toward profitability. As always, these observations are informational and should be weighed alongside a full review of the company's disclosures.
AI Tools in My Analysis Workflow
When preparing for earnings like this one, I often turn to Tickeron’s AI Screener to quickly filter biotech names and spot sector patterns. It helps me compare fundamentals and technical signals across peers without spending hours on manual work. From what I see, these kinds of tools fit naturally into a broader research process rather than replacing traditional due diligence.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ACIU in downward trend: price dove below 50-day moving average on October 06, 2026
ACIU moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend. In 47 of 51 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ACIU as a result. In 72 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The 10-day moving average for ACIU crossed bearishly below the 50-day moving average on October 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 75%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACIU declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for ACIU entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for ACIU's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 52 of 66 cases where ACIU's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
Following a +4.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACIU advanced for three days, in 171 of 230 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
ACIU may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 34 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. ACIU’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.824) is normal, around the industry mean (3.104). P/E Ratio (-4.791) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.070) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (12.547) is also within normal values, averaging (439.647).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACIU’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of therapeutic and diagnostic products to prevent and modify diseases caused by misfolding proteins
Industry Biotechnology
Advertisement